A nuclear receptor in thyroid malignancy: Is PAX8/PPARγ the Holy Grail of follicular thyroid cancer?

European Journal of Endocrinology

Volumn 144, Issue 5, 2001, Pages 453-456

  Führer, Dagmar ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V ANTIGEN; CELL NUCLEUS RECEPTOR; GALECTIN 3; GLYCOPROTEIN; HORMONE RECEPTOR; HYBRID PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIAZOLIDINEDIONE DREIVATE; THYROID PEROXIDASE; THYROID TRANSCRIPTION FACTOR PAX 8; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPIRATION BIOPSY; BREAST LESION; CHROMOSOME 2Q; CHROMOSOME 3P; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 3; CONTROLLED STUDY; DRUG MECHANISM; EXON; FUSION GENE; HUMAN; IMMUNOREACTIVITY; KARYOTYPE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STAINING; THYROID FOLLICULAR CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0343773055     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1440453     Document Type: Article

References (19)

1. Gharib H. Changing concepts in the diagnosis and management of thyroid nodules. Endocrinology and Metabolism Clinics of North America 1997 26 777-800.
2. Löwhagen T & Linsk J. Aspiration biopsy cytology of the thyroid gland. In Clinical aspiration cytology. Eds JA Linsk & S Franzen. New York: Lippincott, 1989.
3. De Micco C, Ruf J, Chrestian MA, Gros N, Henry JF & Carayon P. Immunohistochemical study of thyroid peroxidase in normal, hyperplastic and neoplastic thyroid tumors. Cancer 1991 67 3036-3041.
4. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG & Bartolazzi A. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. Journal of Clinical Oncology 1999 17 3494-3502.
5. Kroll T, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM et al. Pax8-PPARγ1 fusion in oncogene human thyroid carcinoma. Science 2000 289 1357-1360.
6. Herrmann MA, Hay ID, Bartelt DH, Ritland SR, Dahl RJ, Grant CS et al. Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers. Journal of Clinical Investigation 1991 88 1596-1604.
7. Desvergne B & Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 1999 20 649-688.
8. Tontonoz P, Singer S, Formann BM, Sarraf P, Fletcher JA, Fletcher CD et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. PNAS 1997 94 237-241.
9. Mehta RG, Williamson E, Patel MK & Koeffler HP. A ligand of peroxoisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions. Journal of the National Cancer Institute 2000 92 418-423.
10. Elstner K, Müller C, Koshizuka K, Williamson EA, Park D, Asou H et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoid acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. PNAS 1998 95 8806-8811.
11. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA & Law RE. Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1 S transition in vascular smooth muscle cells. Journal of Biological Chemistry 2000 275 22435-22441.
12. Guan YF, Zhang YH, Breyer RM, Davis L & Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPAR-gamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999 10 330-339.
13. Chang TH & Szabo R. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Research 2000 60 1129-1138.
14. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS et al. Effects of ligand activation of peroxisome proliferator-activated receptor in human prostate cancer. PNAS 2000 97 10990-10995.
15. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Research 1998 58 3344-3352.
16. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nature Medicine 1998 4 1046-1052.
17. Hu E, Kim JB, Sarraf P & Spiegelmann BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 1996 274 2100-2103.
18. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M et al. Terminal differentiation of human breast cancer through PPAR gamma. Molecular Cell 1998 1 465-470.
19. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Molecular Cell 1999 3 799-804.